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The present study evaluated the clinical significance of long-term psy-
choanalytic treatment in four groups of about 60 patients in different 
phases of treatment (before, during, after, follow-up) with norma-
tive comparisons on four symptom questionnaires (SCL-90, BDI-II, 
STAI, IIP-64) and two personality assessment instruments (MMPI-2, 
Rorschach-CS). In each group, the proportion of patients with clini-
cally elevated scores was calculated by comparing their scores with 
clinical and nonclinical reference groups for each instrument. The 
authors also calculated a combined percentage of clinically elevated 
scores based on the six instruments as a conservative estimate of 
improvement to nonclinical levels after long-term psychoanalytic 
treatment. Compared to pretreatment levels, the authors found a 
significant decrease in the percentage of clinical cases after treatment. 
For the personality assessment, these results became even more evi-
dent at follow-up. It appears that long-term psychoanalytic treatment 
was clinically significant for patients with chronic mental disorders. 
In the discussion, the authors point out that the evaluation of clinical 
significance at group level should be followed by an examination of 
individual changes over a longer period of time. (Bulletin of the Men-
ninger Clinic, 73[1], 7–33)
Nowadays, psychotherapy outcome research  does not focus sole-
ly on the statistical significance of treatment effects, but also on 
the clinical significance of the results by comparing test scores to 
normative samples. Normative comparisons provide evidence for 
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the clinical significance of therapeutic interventions (Kendall & 
Grove, 1988; Kendall & Norton-Ford, 1982). This approach dif-
fers from studying treatment outcome using traditional pre- versus 
post-treatment group mean comparisons in the sense that norma-
tive comparisons focus on whether or not the end-state function-
ing falls within the normative range on relevant outcome measures 
(Jacobsen, Follette, & Revenstorf, 1984; Kendall, Marrs-Garcia, 
Nath, & Sheldrick, 1999). This way, one can determine whether or 
not the therapeutic change has made a practical, beneficial impact 
on the patient’s life. The assessment of clinical significance rep-
resents an important step forward in the evaluation of treatment 
effects (Kazdin, 1999). 
For patients, therapists, and researchers, returning to nor-
mal functioning is probably one of the most important aspects 
of treatment outcome. There are numerous ways to assess clini-
cal significance (e.g., Atkins, Bedics, McGlinchey, & Beauchaine, 
2005; Bauer, Lambert, & Nielsen, 2004; Jacobsen, Roberts, Berns, 
& McGlinchey, 1999; Ogles, Lunnen, & Bonesteel, 2001; Wise, 
2004). Outcome studies that assess clinical significance can focus 
on whether on not test scores of a person fall below or above a 
certain threshold (usually referred to as normative comparisons), 
and/or focus on the actual amount of change (usually referred to as 
reliable change; Jacobsen & Truax, 1991). In this cross-sectional 
multicohort study, we used the first method to assess the clinical 
significance of long-term psychoanalytic treatment. 
Normative comparisons tell us how the patient’s level of func-
tioning after treatment relates to that of the “functional” popula-
tion and/or the “dysfunctional” population (Jacobsen et al., 1984; 
Jacobson & Truax, 1991; Kendall et al., 1999). Assessing reliable 
change is not possible in a cross-sectional study due to a lack of 
outcome data on changes within individuals on all instruments. 
The main research question was whether long-term psychoanalytic 
treatment is effective in returning patients to normal functioning 
and reducing the number of clinical cases by comparing outcomes 
with data from normative samples. 
Evaluating the clinical significance of two forms of long-term 
psychoanalytic treatment (psychoanalysis and psychoanalytic psy-
chotherapy) is particularly interesting because of the high intensity 
of the clinical input provided. In several countries (e.g., Norway, 
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Belgium, Germany, Canada, the Netherlands), governments still 
provide funding for these two forms of treatment, although research 
into its effectiveness has only recently become more substantial. 
Recent meta-analyses point out that psychoanalytic treatment has 
proven to be an effective treatment for depression (Leichsenring, 
2001) and personality disorders (Leichsenring & Leibing, 2003). 
Previous results from regular clinical practice had already shown 
that 91% of the patients presented substantial psychopathology, 
with especially high levels of depressive problems and (anxious) 
personality pathology at onset of long-term psychoanalytic treat-
ment (Berghout & Zevalkink, 2008). 
This was in line with findings from other studies. Patients at 
onset of psychoanalytic treatment were found to score significantly 
higher on general symptomatology (SCL-90-R), depression (BDI-
II), anxiety (STAI), and interpersonal problems (IIP-64) compared 
to nonclinical norm groups, although not all patients had clinically 
elevated scores on all instruments (Finland: Knekt & Lindfors, 
2004; Germany: Brockmann, Schlüter, Brodbeck, & Eckert, 2002; 
Leichsenring, Biskup, Kreische, & Staats, 2005; Pushner, Kraft, & 
Bauer, 2004; Sweden: Blomberg, Lazar, & Sandell, 2001; Sandell et 
al., 2000; US: Vaughan et al., 2000). The next question we asked 
ourselves was whether or not psychoanalytic treatment can reduce 
this high number of clinical cases. 
From the literature, we learned that several research studies re-
ported on improvement rates and reduction in percentage of clinical 
cases. An early review by Bachrach, Galatzer-Levy, Skolnikoff, and 
Waldron (1991) found improvement rates between 60% and 90% 
in returning patients to normal functioning as reported by clini-
cians. More recently, Leichsenring et al. (2005) reported that about 
80% of the patients in psychoanalysis showed clinically significant 
improvements on symptomatic functioning at the end of treatment 
and at a 1-year follow-up. Sandell et al. (2000) assessed the pro-
portion of patients that could be identified as “clinical cases” on 
the basis of three outcome measures in different phases of psycho-
analysis and psychoanalytic psychotherapy. For psychoanalysis, 
88% of their patients were clinical cases before treatment, with a 
substantial reduction to 33% clinical cases 3 years after treatment 
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termination as measured with a composite measure consisting of 
SCL-90, SAS, and SOCS. 
In the psychoanalytic psychotherapy group, there was a more 
modest decrease in the percentage of clinical cases, from 67% 
before treatment to 45% three years after treatment termination 
(Sandell et al., 2000). Grande et al. (2006) also studied the clinical 
significance of psychoanalysis and psychoanalytic psychotherapy 
and found significant results after treatment. For general psycho-
pathology (SCL-90-R GSI), they found that 61% of the patients 
in psychoanalysis and 37% of the patients in psychoanalytic psy-
chotherapy had posttreatment scores within the nonclinical range. 
With regard to the level of interpersonal problems (IIP-64 total 
score), 47% of the patients in psychoanalysis and 27% of the pa-
tients in psychoanalytic psychotherapy were at nonclinical levels 
after treatment. At follow-up, results were in the same direction, 
but no longer statistically significant (Grande et al., 2006). On the 
basis of these previous findings, we also expected to find a signifi-
cant reduction in the number of patients with clinically elevated 
scores after psychoanalytic treatment as compared to our pretreat-
ment group, and in particular better results for psychoanalysis than 
for psychoanalytic psychotherapy. 
We examined the clinical effectiveness of long-term psychoan-
alytic treatment by investigating the proportion of patients with 
clinically elevated scores on four symptom measures and two per-
sonality assessment instruments in different phases of treatment. 
Because of the diversity and complexity of patients’ problems, it 
is sensible to use multiple outcome measures for evaluating the 
clinical significance of treatment (Hill & Lambert, 2004). The six 
instruments assess different areas of functioning and thus provide 
a broad perspective on therapy outcome (Kendall et al., 1999). 
Normative data of functional and dysfunctional populations were 
available for these instruments and were usually reported in the 
test manuals of the outcome measures. These data provide reliable 
estimates of general and/or clinical population parameters. 
First, scores on the symptom measures and personality assess-
ment instruments were analyzed separately. After that we calcu-
lated a combined index, which provided a conservative estimate 
of improvement after long-term psychoanalytic treatment based 
on the six instruments taken together. In the assessment of clinical 
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cases, we followed other researchers who had shown that it is pos-
sible to use statistically defined cutoff values and combine differ-
ent instruments to come to a global assessment of the percentage 
of clinical cases in a certain patient population (Blomberg et al., 
2001; Puschner, Kraft, Kächele, & Kordy, 2007; Rudd et al., 1996; 
Sandell et al., 2000). 
Method
Subjects
The total sample consisted of 231 subjects from four mental health 
care organizations (Nederlands Psychoanalytisch Instituut, De 
Gelderse Roos, Mediant, Parnassia/Psy-Q). The majority of our 
sample (73%) were women. The age range of our subjects ranged 
from 19 to 68 years, with an average age of 36 years (SD = 8.4). 
We found that 77% of all subjects had received previous (psycho-)
therapeutic treatment before applying for long-term psychoana-
lytic treatment. Further, we found that 44% of the subjects were 
living with a partner, 21% had children, 92% had a Western cul-
tural background, 76% had received higher education, and 79% 
was unemployed. Most frequently diagnosed DSM-IV Axis I dis-
orders were mood disorders (47%), particularly dysthymic disor-
der (30%). With regard to Axis II diagnoses, we found that the 
majority of the patients (73%) were diagnosed with a personality 
disorder.
In this study, we used a cross-sectional design with four differ-
ent cohorts. These cohorts were representative samples of patients 
from different phases of treatment. The subjects were not random-
ly assigned to the cohorts or treatments but followed a naturalis-
tic route through the clinical setting. This ensures high external 
validity and generalizabilty of the findings (Leichsenring, 2004; 
Seligman, 1995; for a more extensive description of the methodol-
ogy, cf. Zevalkink & Berghout, 2006). The advantage of such a 
research design is that we can obtain information about the effects 
of long-term treatments within a relatively short period of time (de 
Maat, Dekker, Schoevers, & de Jonghe, 2007; Sandell, Blomberg, 
& Lazar, 1997). By investigating the necessary information on 
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patient characteristics and controlling for potential pretreatment 
differences, we intended to make the four cohorts as equivalent 
as possible regarding baseline characteristics (Bickman & Rog, 
1998). The pretreatment cohort (n = 64) consisted of patients who 
had just started long-term psychoanalytic treatment; in the during-
treatment cohort (n = 49) patients were 1 year into treatment; the 
end-of-treatment cohort (n = 67) consisted of persons who had 
just finished (approximately 3 months after treatment termination) 
long-term psychoanalytic treatment; and persons in the follow-up 
cohort (n = 51) had already finished their treatment 2 years ago. 
Inclusion criteria for participation were a minimum age of 18 
years, having mastery of the Dutch language, and assignment for 
long-term psychoanalytic treatment (>25 sessions or >1 year, with 
a minimum frequency of once a week). Exclusion criteria were the 
presence of (acute) psychotic symptoms. In each cohort, about 40% 
of the patients received psychoanalysis (PA) and 60% received psy-
choanalytic psychotherapy (PP). There were no significant differ-
ences across cohorts regarding the PA/PP distribution. Chi-square 
analyses and ANOVAs revealed no significant differences between 
the four cohorts on pretreatment (sociodemographic) patient char-
acteristics (sex, treatment history, living situation, cultural back-
ground, educational level, source of income, DSM-IV Axis I di-
agnosis), except for age at intake and DSM-IV Axis II diagnosis. 
Subjects in the end-of-treatment cohort appeared to be somewhat 
younger at the start of treatment compared to subjects in the other 
cohorts (F = 3.68, p < .05, maximum difference of 3.2 years). The 
frequencies of Axis II diagnoses were roughly comparable across 
the four cohorts; however, in the pretreatment and during-treat-
ment cohorts, there were significantly more patients with a person-
ality disorder diagnosis at the start of treatment compared to the 
other two cohorts (χ² = 16.86, p < .01).
Treatments
Both psychoanalytic psychotherapy and psychoanalysis are open-
ended long-term psychotherapeutic treatments, defined as consist-
ing of 25 sessions or more and lasting more than 1 year. These 
psychoanalytic treatments have been described in textbooks (e.g., 
Etchegoyen, 1991; Greenson, 1967; Luborsky, 1984; Mitchell & 
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Black, 1995; Pine, 1990, 1998; Wallerstein, 1995). Efforts have 
been made to manualize psychoanalytic treatment, but so far this 
work has been complicated by the relative long duration of the 
treatment and the complexity of the technique. In general, psycho-
analytic treatments share some common theoretical assumptions 
and intend to influence the working of unconscious processes by 
either focusing on conflicts, object relations, the self, and/or inter-
actional processes (Gabbard, 2005; de Wolf, 2002). Psychoanaly-
sis differs from psychoanalytic psychotherapy in that patients in 
psychoanalysis receive three or more sessions per week lying on 
the couch, while patients in psychoanalytic psychotherapy sit face-
to-face and the frequency typically is one or two times a week. The 
average length of treatment was 6.5 years for PA (SD = 2.7 yrs.) 
and 3.9 years for PP (SD = 2.5 yrs.). As could be expected, this dif-
ference in treatment duration was significant (F = 29.0, p <.001). 
All therapists (N = 94) in the project are licensed clinicians (psy-
chiatrists/ psychotherapists or psychologists/psychotherapists) and 
members of one of the Netherlands psychoanalytic societies.
Measures
In line with methodological recommendations, we used multiple 
outcome measures and data collection methods to enhance validity 
(Bickman & Rog, 1998). For this project, four symptom measures 
(SCL-90-R, BDI-II, STAI, IIP-64) and two personality instruments 
(MMPI-2 and Rorschach-CS) were selected.
Symptom measures. The SCL-90-R measures symptoms in nine 
major areas of the patient’s psychological, somatic, and interper-
sonal functioning. The 90 items are scored on a 5-point Likert 
scale (Derogatis, 1983). In the Netherlands, norms and transla-
tions were developed by Arrindell and Ettema (2003). The 21-item 
BDI-II measures depressive symptoms, scored on a 4-point Likert 
scale (Beck, Steer, & Brown, 1996). In the Netherlands, van der 
Does (2002) translated the BDI-II and developed norm scores. The 
40-item STAI assesses state and trait anxiety, scored on a 4-point 
Likert scale (Spielberger, 1983). State anxiety reflects a momentary 
anxiety, and trait anxiety refers to a general tendency to respond 
with anxiety to perceived threats in the environment. The STAI 
was published in the Netherlands and norm scores were developed 
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by van der Ploeg (2000). The IIP consists of 64 items, scored on a 
5-point Likert scale, that assess perceived interpersonal difficulties 
on eight subscales (Horowitz, Alden, Wiggins, & Pincus, 2000). 
Clinical norm scores were derived from Horowitz, Strauss, and 
Kordy (1994). For each of the questionnaires we used only the 
total or overall sum scores. 
Personality assessment. The MMPI-2 (Butcher, Dahlstrom, Gra-
ham, Tellegen & Kaemmer, 1989), a 567-item self-report ques-
tionnaire, aims to quantitatively measure an individual’s level of 
emotional adjustment and attitude toward test taking, resulting in 
clusters of personality variables (Groth-Marnat, 1997). In concor-
dance with other research on the MMPI-2, we did not use scale 
5-Masculinity-Femininity (Mf), because this scale is usually not 
considered as a clinical scale that measures psychopathology (e.g., 
Nieberding et al., 2003; Terlidou et al., 2004). Derksen, de Mey, 
Sloore, and Hellenbosch (2006) translated the MMPI-2 and devel-
oped norms for use in the Netherlands. 
The Rorschach inkblot test measures different dimensions of 
personality functioning and has been used as a diagnostic tool and 
outcome instrument in psychoanalytic treatment for quite some 
time (e.g., Ganellen, 1996; Grønnerød, 2004; Viglione, 1999). It 
assesses clients’ personality structure, with particular emphasis on 
understanding how they respond to and organize their environ-
ment. In this way, it can also be considered a measure of perception 
and association (Weiner, 1998). It consists of a set of 10 bilaterally 
symmetrical inkblots on sturdy cards. Three psychologists with ex-
tensive training and experience in the Comprehensive System (CS) 
scored the Rorschach (Exner, 2001, 2003). A number of variables 
were selected that were found to be important in assessing differ-
ences as a result of psychotherapeutic treatment. 
We selected eight variables of the CS (the six Special Indices, 
EII-2, AdjD) because those are assumed to be global measures of 
personality functioning. Based on age and sex-differentiated norms 
of clinical and nonclinical reference groups, the CS produces ag-
gregate scores on six Special Indices: Perceptual-Thinking (PTI), 
Depression (DEPI), Coping Deficit (CDI), Suicide Constellation (S-
CON), Hypervigilance (HVI), and Obsessive Style (OBS). The Ego 
Impairment Index (EII-2) is a relatively new Rorschach composite 
and measures psychological impairment and thought disturbance 
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(Viglione, Perry, & Meyer, 2003). The Adjusted D score (AdjD) 
score gives an indication of whether a person typically has adequate 
resources to manage problems. Norm scores for the Rorschach-CS 
were derived from Exner (2001). 
Procedure
All patients who met the inclusion criteria were approached via 
mail. An informed consent with a return envelope was enclosed 
in the letter as well. In total we approached 383 persons to par-
ticipate, of which 247 (65%) persons said “Yes,” 81 (21%) said 
“No,” and 55 (14%) never responded. Of the 247 persons who 
agreed to participate, 16 eventually did not participate in the study 
for varying reasons (e.g., withdrawal from the study, never started 
the psychoanalytic treatment). Chi-square analyses and ANOVAs 
showed that these 16 dropouts did not differ significantly (p < .05) 
on pretreatment sociodemographic and diagnostic characteristics 
from the 231 subjects who actually did participate. When subjects 
returned a positive informed consent, we telephoned them to make 
an appointment for the personality assessment (MMPI-2 and Ror-
schach-CS). At that time, we also sent them the symptom question-
naires by regular mail. They could send these questionnaires back 
in a stamped envelope. Data gathering was done between January 
2004 and June 2007. The personality assessments were done by re-
searchers, psychologists, clinicians and research assistants trained 
in administering the Rorschach. 
Data analyses
We investigated the raw Rorschach data and evaluated whether 
the Rorschach protocols in all four cohorts were equally complex. 
After computing z-scores for R (number of responses) and Form% 
(measure of defensiveness), we computed a summary index of com-
plexity by calculating the average z-scores after reversing the direc-
tion of the Form% variable. We found no significant differences 
in R, Form%, and response complexity. The values indicate that 
overall we are dealing with high R–low Lambda patients, that is, 
persons who give rich and elaborate responses. In line with Meyer 
(1992, 1993), we corrected for the influence of R (number of re-
sponses) on the raw scores by dividing all raw scores by R and 
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multiplying by 20.25. The multiplier is the average R in the adult 
outpatient norm group (Exner, 2001). With raw scores no longer 
confounded by variations in R, structural data would be easier to 
interpret and more suitable for research purposes (Meyer, 1992, 
1993). Missing values (4.8%) were replaced by the mean group 
average of the corresponding cohort.
Next, we calculated the percentages of patients who scored 
above (or below) a certain cutoff on the different assessment in-
struments. One of the most often used, and perhaps the least ar-
bitrary, is a cutoff based on information from both functional and 
dysfunctional populations (cutoff C) that allows precise determina-
tion of which population a subject’s score belongs in (Jacobsen et 
al., 1984; Jacobsen & Truax, 1991). According to this definition, 
a clinically elevated score is defined as a score that is closer to the 
mean of the clinical population than to the nonclinical population. 
The formula for the calculation of this cutoff value is as follows: 
(SD0 × M1) + (SD1 × M0) Cutoff = ——————————
(SD0 + SD1)
where 
M0  = mean score in the nonclinical reference group,
SD0  = standard deviation in the nonclinical reference group,
M1  = mean score in the clinical reference group, and
SD1  = standard deviation in the clinical reference group.
The cutoff values of the four symptom measures and the MMPI-2 
scales are shown in Table 1. In the following, we have reported 
the chi-square analyses of the differences between the pretreatment 
cohort and the end-of-treatment cohort as well as those between 
the pretreatment cohort and the follow-up cohort. Raw percent-
age data are reported for all cohorts. Chi-square analyses revealed 
no significant differences between the pretreatment cohort and the 
during-treatment cohort in the number of patients with clinically 
elevated scores on both the symptom measures and the two per-
sonality measures. Therefore, the next results will only show pro-
portions for the during-treatment cohort in the tables. Chi-square 
analyses revealed no significant differences between PA and PP pa-
tients on initial impairment or treatment outcome. Therefore, we 
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report the aggregated results from both patient groups together as 
one large group. 
Results
Symptom measures
Table 2 shows the percentages of patients with clinically elevated 
scores on the symptom measures in the different phases of treat-
ment. Chi-square analyses revealed significant differences on all 
four questionnaires between the pretreatment group and the end-
of-treatment and follow-up groups in number of patients with 
clinically elevated scores. 
Personality assessment
Table 3 shows the percentages of patients with clinically elevated 
scores on the MMPI-2 clinical scales in the different phases of treat-
ment. The results show significant decreases in the percentage of 
patients with clinically elevated scores on several MMPI-2 clinical 
scales, but not on all scales. Pretreatment versus end-of-treatment 
comparisons revealed significant differences in the number of pa-
tients with elevated scores on the scales for Depression, Hysteria, 
Psychopathic Deviate, Psychasthenia, and Social Inhibition. And 
with our pretreatment versus follow-up comparisons we found sig-
nificant effects on the scales for Depression, Psychopathic Deviate, 
and Psychasthenia.
Table 4 shows the percentages of patients with clinically elevat-
ed scores on the Rorschach scales in the different phases of treat-
ment. We found a significant decrease in the percentage of patients 
with an elevated score on the Perceptual Thinking Index (PTI). On 
the other Rorschach scales, we did not find significant decreases in 
the proportion of patients with clinically elevated scores. Second-
ary analyses on the potential differential effect of treatment type 
revealed that the decrease in clinically elevated scores on the PTI 
was mainly due to patients in psychoanalysis. Post-hoc chi-square 
analyses revealed significant differences in the number of clinical-
ly elevated scores on the PTI between pretreatment and end-of-
treatment (24% vs. 3%, χ² = 5.46, p < .05) and a statistical trend 
between pretreatment and follow-up (24% vs. 5%, χ² = 3.49, p 
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< .10) in the PA-group, but no significant differences between the 
cohorts in the PP group.
Combining instruments: Clinical cases across instruments
After investigating the percentage of clinical cases for each in-
strument separately, we combined the test scores from the four 
symptom measures and calculated the percentages of patients who 
scored within the clinical range on at least two symptom measures. 
In comparison to the pretreatment cohort, results showed a signifi-
cant reduction in the number of patients with clinically elevated 
scores on at least two symptom measures at the end of treatment 
(75% vs. 18%) and at follow-up (75% vs. 26%) (see Table 5). 
With regard to the MMPI-2, we found a significant reduction in 
the number of patients who had clinically elevated scores on at 
least two MMPI-2 clinical scales at treatment termination and at 
follow-up. On the Rorschach-CS, we found a significant reduction 
in the percentage of patients with at least two clinically elevated 
Rorschach indices at follow-up but not at the end of treatment. 
Finally, we combined the results from the symptom measures 
with the personality assessment instruments and we redefined a 
clinical case as someone who fulfilled at least two of the three fol-
lowing criteria: (1) clinically elevated scores on at least two symp-
tom measures; (2) clinically elevated scores on at least two MMPI-2 
clinical scales; and (3) clinically elevated scores on at least two Ror-
schach indices. Based on this definition, a significant reduction in 
the percentage of clinical cases after psychoanalytic treatment was 
found both after treatment (84% vs. 41%) and at follow-up (84% 
vs. 40%) compared to the percentage of patients before treatment. 
The still relatively high number of clinical cases after treatment was 
mainly due to the results of the personality assessments.
Further, we performed exploratory analyses to identify the char-
acteristics of the subjects with the most unfavorable treatment out-
come. From the end-of-treatment and follow-up cohorts, we distin-
guished six subjects with clinically elevated scores on the symptom 
measures and on the MMPI-2 and on the Rorschach-CS. Socio-
demographic characteristics of this small subgroup did not differ 
significantly from those with more favorable treatment outcome. 
Examination of pretreatment DSM-IV diagnoses did show that all 
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six subjects (100%) were diagnosed with a personality disorder at 
the start of treatment, whereas 60% of the patients with a more 
favorable treatment outcome were diagnosed with a personality 
disorder at the start of treatment (χ² = 3.84, p < .10). 
Discussion
In this study, we investigated the clinical significance of long-term 
psychoanalytic treatment by examining the percentage of patients 
considered to function normally (i.e., at nonclinical levels) in dif-
ferent phases of treatment. The vast majority of patients were iden-
tified as clinical cases before treatment on the basis of six instru-
ments measuring both symptoms and personality functioning. After 
treatment, we found a significant decrease in the number of clinical 
cases, and these results became even more evident at follow-up for 
the personality assessment. The results of these normative com-
parisons signify clinically meaningful improvements in real life. 
In particular, our results showed large reductions in the number 
of patients with clinically elevated scores on the symptom mea-
sures, but also significant improvements on the personality mea-
sures. These results are in line with other studies on the clinical 
significance of psychoanalytic treatment (Grande et al., 2006; Le-
ichsenring et al., 2005; Perry, Banon, & Ianni, 1999; Sandell et 
al., 2000). Thus far, the evaluation of clinical significance in treat-
ment outcome research has mainly emphasized symptom reduction 
(Kazdin, 1999). The current study can be considered a valuable 
addition to the literature because of the comprehensive personality 
assessment of each patient. 
The long-term effects of psychoanalytic treatment were particu-
larly apparent on the MMPI-2 scales for Depression, Psychopath-
ic Deviate, and Psychasthenia. This means that the presence and 
depth of depression, the level of social maladjustment and feelings 
of alienation, and the level of (social) anxiety and self-doubt were 
all substantially reduced after long-term psychoanalytic treatment. 
Furthermore, at 2-year follow-up, we still found significant differ-
ences with the pretreatment group on these personality variables. 
Apparently long-term psychoanalytic treatment is especially ef-
fective in returning patients to normal functioning in these areas 
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and sustaining these improvements over a longer period of time. 
These variables appear to play an important role in treatment mon-
itoring, in the sense that improvements in these areas could be ex-
pected after being in psychoanalytic treatment. The other MMPI-2 
variables appear to be more stable and therefore less suitable to 
monitor change in psychoanalytic treatment. 
Overall, we found substantial decreases in the number of patients 
with clinically elevated scores on all instruments, but the effects on 
the Rorschach-CS were the smallest. Perhaps this is because the 
global indices of the Rorschach-CS give us an estimation of our 
most stable personality traits, and on this level of functioning one 
would obviously expect the least changes. On an idiosyncratic lev-
el, the Rorschach-CS is an invaluable instrument to identify some-
one’s strong as well as weak points and use this information for 
thorough clinical decision making before treatment. 
Although several studies have shown that the Rorschach-CS can 
also be a valuable instrument in monitoring treatment outcome 
(e.g., Ganellen, 1996; Grønnerød, 2004; Viglione, 1999; Weiner 
& Exner, 1991), we found that using the global indices of the 
Rorschach-CS for measuring treatment outcome when comparing 
groups of patients appeared to be less useful. However, the com-
bined score showed a significant decrease in clinical cases—as mea-
sured with the Rorschach—at 2-year follow-up. This might also 
be interpreted as a postponed sleeper effect of the psychoanalytic 
treatment on structural personality aspects, such as reduction of 
distrust in others (HVI) and better reality testing (PTI). 
Although we found encouraging results about the clinical sig-
nificance of psychoanalytic treatment effects, there was still a siz-
able proportion of patients with clinically elevated scores on our 
assessment instruments after treatment. For instance, 18% of the 
patients still had clinically elevated scores on the MMPI-2 Depres-
sion scale at the end of treatment, for the BDI-II this percentage 
was 13%; and on the Depression scale of the Rorschach-CS this 
percentage was 18%. These results are in line with findings from a 
review of psychotherapy for depression, which suggested that most 
treated patients did show progress but were still more depressed 
than normative samples (Robinson, Berman, & Neimeyer, 1990). 
As Wise (2004) also pointed out, a complete return to normal func-
tioning might not be realistic for intensive outpatient treatments. It 
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could be that certain patients went through substantial change but 
at the end of treatment were still not functioning in the normative 
range. 
In the literature, these cases are normally referred to as improved, 
in contrast to recovered (Jacobsen & Truax, 1991). However, with 
our cross-sectional research design we were not able to examine 
these individual changes. Our exploratory analyses showed that 
the subjects with the most unfavorable treatment outcome were 
all diagnosed with a personality disorder at the start of treatment, 
while in the subgroup of patients with a more favorable treatment 
outcome, 60% were diagnosed with a personality disorder at the 
start of treatment. This could mean that the presence of a person-
ality disorder can have a detrimental effect on treatment outcome; 
however, it does not necessarily mean that all patients with a per-
sonality disorder will have an unfavorable treatment outcome. 
In the research literature there is a growing body of evidence 
that patients with a personality disorder have worse treatment out-
come compared to those without a personality disorder (e.g., Digu-
er, Barber, & Luborsky, 1993; Newton-Howes, Tyrer, & Johnson, 
2006; Reich, 2003; Shea, Widiger, & Klein, 1992). Our exploratory 
findings are in line with these results, but further research is needed 
to identify exactly which patient/therapist/treatment characteristics 
are reliable predictors of an unfavorable treatment outcome, so 
that the treatment may be contraindicated in the future for certain 
subgroups or subtypes of patients.
Another noteworthy finding was that the number of clinical cas-
es after 1 year of treatment was comparable to that before treat-
ment. In contrast to often found symptom decreases within the 
first year of (short-term) psychotherapy (Howard, Kopta, Krause, 
& Orlinsky, 1986; Kopta, Howard, Lowry, & Beutler, 1994), the 
current study shows that in this particular patient population the 
level of symptoms and personality problems does not decrease 
rapidly, justifying a longer treatment process. Moreover, we found 
that 77% of the patients had already tried a previous (short-term) 
treatment, which strengthens our belief that we are dealing with a 
patient population with chronic symptoms/problems that are per-
haps more resistant to change and require a more intensive form 
of therapy, such as long-term psychoanalytic treatment. It appears 
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that patients in psychoanalytic treatment follow a different (and 
slower) pattern of change compared to those in short-term thera-
pies, which are primarily focused on symptom reduction. This hy-
pothesis could be further investigated by performing growth curve 
analyses to study the exact trajectories of symptoms and personal-
ity functioning in long-term psychoanalytic treatment.
The definition of clinical significance and the selection of instru-
ments are crucial in this discussion. Because there is a lack of con-
sensus regarding what measures are the most appropriate in assess-
ing the clinical significance of treatment effects, it is recommended 
that multiple measures be used simultaneously. In this we followed 
other studies (Blomberg et al., 2001; Derogatis & Lazarus, 1994; 
Puschner et al., 2007; Rudd et al., 1996; Sandell et al., 2000) and 
tried to make an even more conservative estimate of the number 
of clinical cases. Of course, clinical significance also depends on 
the goals of treatment and the nature of the problems of the pa-
tient population (Foster & Mash, 1999; Kazdin, 1999). Because 
the goals of long-term psychoanalytic treatment are both structural 
and symptomatic change, we used personality assessment instru-
ments as well as symptom questionnaires. 
Another essential issue is the selection of normative data. Ting-
ey, Lambert, Burlingame, and Hansen (1996) pointed out that al-
though identifying normative reference groups is essential in evalu-
ating clinical significance, here too there is a lack of consensus or 
guidelines for selecting these groups. As an addition to the clini-
cal significance literature, they proposed a four-group distinction 
(asymptomatic, mildly symptomatic, moderately symptomatic, 
severely symptomatic) instead of a two-group (clinical and non-
clinical) distinction for a more sensitive analysis of clinical signifi-
cance. However, in practice, most measures only have established 
norms for a functional and a dysfunctional population and not 
for groups that are somewhere in between. Tingey et al. (1996) 
do touch on an important issue however, because the selection of 
the reference groups determines the cutoffs directly and therefore 
can significantly influence the results. So in this, we are dependent 
on the availability, quality, and representativeness of the reference 
groups that are mentioned in the manuals of the assessment instru-
ments. For the MMPI-2, we used a clinical sample of outpatients 
patients with relatively mild distress. Consequently, the means of 
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the MMPI-2 scales in the nonclinical and clinical norm groups 
were located fairly close to each other. This could perhaps explain 
why we still found a lot of clinically elevated scores on the MMPI-2 
scales after treatment, because the cutoff values that distinguish 
between nonclinical and clinical were relatively low. More research 
is needed to evaluate alternative cutoff points and their utility in 
distinguishing between clinical and nonclinical groups. 
In multiple-cohort designs a potential form of confounding 
involves differences in background characteristics and level of 
pretreatment psychopathology between the cohorts (Cogan & 
Porcerelli, 2005). One cannot be sure that the patients enrolled 
in the various cohorts were exactly equivalent in terms of base-
line psychopathology and background characteristics. It could be 
that patients with more psychopathology might be more apt to 
drop out of treatment and, in selecting subjects for the two post-
treatment samples, we may have included more subjects who were 
relatively higher-functioning at the start of treatment compared to 
the other two cohorts. This could potentially influence the results 
of our cohort comparisons. In the present study, we compared the 
four cohorts on pretreatment DSM-IV-R diagnoses and sociode-
mographic characteristics. We found no significant differences on 
most variables, thus providing a strong check for the comparability 
of the four cohorts. 
Another issue to keep in mind is that age and treatment effects 
could have occurred. Age effects are those associated with personal 
maturation that persons would presumably experience during any 
period of time (Raudenbush & Chan, 1992). With regard to treat-
ment effects, one could argue that it is impossible to know whether 
the improvements we found are actually attributable to the treat-
ment given. It is not possible to draw causal inferences from the 
presented data. We have to be careful in drawing conclusions about 
the clinical significance of both treatments. A related issue is that in 
cross-sectional studies, ideas about changes within individuals can-
not be tested. We are only able to talk about differences between 
patients on a group level and not of individual changes in patients 
over time. Therefore, we encourage further studies on the clinical 
significance of long-term psychoanalytic treatment effects that also 
investigate reliable changes on an individual level.
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Although the present study has certain limitations, we think the 
results of our study make a valuable contribution to the evidence 
about the clinical significance of long-term psychoanalytic treat-
ments. The major merits of this study were the large sample size, 
the high external validity, and the comprehensive personality as-
sessment. A large proportion of patients with chronic symptoms 
of depression and personality pathology appeared to profit from 
long-term psychoanalytic treatment. These effects were not yet vis-
ible after 1 year of treatment, but more so at the end of treatment 
and at 2-year follow-up. Psychoanalytic treatment has made a 
practical, beneficial, and clinically relevant impact on the patients’ 
lives, given our findings that the presence and depth of depression, 
the clinical level of social maladjustment and feelings of alienation, 
and the clinical level of (social) anxiety and self-doubt were all sub-
stantially reduced after long-term psychoanalytic treatment. 
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